Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Rink, Johann [VerfasserIn]   i
 Froelich, Matthias F. [VerfasserIn]   i
 McWilliams, Justin P. [VerfasserIn]   i
 Gratzke, Christian [VerfasserIn]   i
 Huber, Thomas [VerfasserIn]   i
 Gresser, Eva [VerfasserIn]   i
 Schönberg, Stefan [VerfasserIn]   i
 Diehl, Steffen J. [VerfasserIn]   i
 Nörenberg, Dominik [VerfasserIn]   i
Titel:Prostatic artery embolization for treatment of lower urinary tract symptoms
Titelzusatz:a Markov model-based cost-effectiveness analysis : health services research and policy
Verf.angabe:Johann S. Rink, Matthias F. Froelich, Justin P. McWilliams, Christian Gratzke, Thomas Huber, Eva Gresser, Stefan O. Schoenberg, Steffen J. Diehl, Dominik Nörenberg
E-Jahr:2022
Jahr:June 2022
Umfang:11 S.
Fussnoten:Online verfügbar: 25. April 2022, Artikelversion:16. Juni 2022 ; Gesehen am 06.02.2024
Titel Quelle:Enthalten in: American College of RadiologyJournal of the American College of Radiology
Ort Quelle:New York, NY : Elsevier, 2004
Jahr Quelle:2022
Band/Heft Quelle:19(2022), 6 vom: Juni, Seite 733-743
ISSN Quelle:1558-349X
Abstract:Purpose - The aim of this study was to investigate whether prostatic artery embolization (PAE) can be considered a long-term cost-effective treatment option in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia in comparison to transurethral resection of the prostate (TURP). - Methods - The in-hospital costs of PAE and TURP in the United States were obtained from a recent cost analysis. Clinical outcomes including nature and rate of adverse events for TURP and PAE along with rates of retreatment because of complications or clinical failure were obtained from peer-reviewed literature. A decision tree-based Markov model was created, analyzing long-term cost-effectiveness for TURP and PAE from a US health care sector perspective. Cost-effectiveness over a time frame of 5 years was estimated while assuming a willingness to pay of $50,000 per quality-adjusted life-year (QALY). The primary outcome was incremental cost-effectiveness ratio. - Results - PAE resulted in overall cost of $6,464.92 and an expected outcome of 4.566 QALYs. In comparison, TURP cost $9,221.09 and resulted in expected outcome of 4.577 QALYs per treatment. The incremental cost-effectiveness ratio for TURP was $247,732.65 per QALY. On the basis of the willingness-to-pay threshold, PAE is cost effective compared with TURP. - Conclusions - On the basis of our model, PAE in comparison with TURP can be regarded as a cost-effective treatment option for patients with lower urinary tract symptoms within the US health care system.
DOI:doi:10.1016/j.jacr.2022.02.040
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1016/j.jacr.2022.02.040
 Volltext: https://www.sciencedirect.com/science/article/pii/S1546144022002757
 DOI: https://doi.org/10.1016/j.jacr.2022.02.040
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:benign prostate hyperplasia
 cost-effectiveness
 lower urinary tract symptoms
 Prostatic artery embolization
 transurethral resection of the prostate
K10plus-PPN:1880026244
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69177827   QR-Code
zum Seitenanfang